Hypothesis 2: GPNMB-CD44 Axis as Anti-inflammatory Pathway

Target: GPNMB, CD44 Composite Score: 0.772 Price: $0.77 Citation Quality: Pending neurodegeneration Status: proposed

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

✓ All Quality Gates Passed

Quality Report Card click to collapse

B+

Composite: 0.772

Top 16% of 681 hypotheses

T5 Contested

Contradicted by evidence, under dispute

C Mech. Plausibility 15% 0.45 Top 86%

C Evidence Strength 15% 0.42 Top 82%

B Novelty 12% 0.60 Top 87%

C+ Feasibility 12% 0.52 Top 63%

C+ Impact 12% 0.50 Top 87%

C Druggability 10% 0.48 Top 72%

C+ Safety Profile 8% 0.55 Top 54%

C+ Competition 6% 0.52 Top 84%

C+ Data Availability 5% 0.55 Top 66%

C Reproducibility 5% 0.42 Top 82%

Evidence

4 supporting | 7 opposing

Citation quality: 0%

Debates

0 sessions

No debates yet

Convergence

0.00 F 30 related hypothesis share this target

Hypotheses from Same Analysis (4)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

Hypothesis 7: SST-SST1R/Gamma Entrainment-Enhanced Astrocyte Secretome

Score: 0.971 | Target: SST, SSTR1, SSTR2

Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse

Score: 0.889 | Target: SLC16A1, SLC16A7, LDHA, PDHA1

Hypothesis 1: MANF/CDNF Signaling as Primary Neuroprotective Effector

Score: 0.818 | Target: MANF, CDNF

Hypothesis 3: HepaCAM-Containing Extracellular Vesicles

Score: 0.762 | Target: HEPACAM1, HEPACAM2

Description

GPNMB secreted by healthy astrocytes protects motor neurons through engagement of CD44 receptor on microglia and neurons, attenuating neuroinflammatory responses that contribute to RBP mislocalization. VCP-mutant hypoxic astrocytes downregulate GPNMB secretion, leading to unchecked microglial activation and TDP-43 phosphorylation.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

11 citations 11 with PMID Validation: 0% 4 supporting / 7 opposing

✓ For (4)

No supporting evidence

No opposing evidence

(7) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 10CLIN 1GENE 0EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
GPNMB protects against neuroinflammation and neuro…	Supporting	MECH	-	-	-	-	PMID:29519253	-
GPNMB ameliorates neuroinflammation through AMPK/N…	Supporting	MECH	-	-	-	-	PMID:38782114	-
CSF GPNMB levels are associated with age and micro…	Supporting	CLIN	-	-	-	-	PMID:39957200	-
Neuroinflammation and glycosylation-related CSF pr…	Supporting	MECH	-	-	-	-	PMID:39624674	-
CRITICAL: Human VCP mutant ALS/FTD microglia displ…	Opposing	MECH	-	-	-	-	PMID:39593143	-
GPNMB evidence primarily from non-motor-neuron sys…	Opposing	MECH	-	-	-	-	PMID:29519253	-
GPNMB is increasingly recognized as a marker of di…	Opposing	MECH	-	-	-	-	PMID:38577970	-
TDP-43 pathology occurs in motor neurons independe…	Opposing	MECH	-	-	-	-	PMID:39593143	-
Receptor specificity ambiguous; CD44 has multiple …	Opposing	MECH	-	-	-	-	PMID:29519253	-
GPNMB may work through TREM2 or other microglial r…	Opposing	MECH	-	-	-	-	PMID:38577970	-
Chronically activated ALS microglia gradually lose…	Opposing	MECH	-	-	-	-	PMID:38577970	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 4

GPNMB protects against neuroinflammation and neuronal loss via CD44 receptor modulation

PMID:29519253

GPNMB ameliorates neuroinflammation through AMPK/NFkappaB signaling pathway regulation

PMID:38782114

CSF GPNMB levels are associated with age and microglial activation in Parkinson's disease, suggesting biomarke…▼

CSF GPNMB levels are associated with age and microglial activation in Parkinson's disease, suggesting biomarker potential

PMID:39957200

Neuroinflammation and glycosylation-related CSF proteins predict functional decline in ALS

PMID:39624674

✗ Opposing Evidence 7

CRITICAL: Human VCP mutant ALS/FTD microglia display immune and lysosomal phenotypes INDEPENDENTLY of GPNMB - …▼

CRITICAL: Human VCP mutant ALS/FTD microglia display immune and lysosomal phenotypes INDEPENDENTLY of GPNMB - direct falsification of central mechanism

PMID:39593143

GPNMB evidence primarily from non-motor-neuron systems; mechanistic data in motor neurons is sparse

PMID:29519253

GPNMB is increasingly recognized as a marker of disease-associated microglia (DAM); elevation may represent co…▼

GPNMB is increasingly recognized as a marker of disease-associated microglia (DAM); elevation may represent compensatory response rather than protective mechanism

PMID:38577970

TDP-43 pathology occurs in motor neurons independently of microglia in many ALS cases

PMID:39593143

Receptor specificity ambiguous; CD44 has multiple isoforms with broad expression including cell adhesion, migr…▼

Receptor specificity ambiguous; CD44 has multiple isoforms with broad expression including cell adhesion, migration, stem cell homing

PMID:29519253

GPNMB may work through TREM2 or other microglial receptors rather than CD44

PMID:38577970

Chronically activated ALS microglia gradually lose their immune functions - not consistent with simple GPNMB-l…▼

Chronically activated ALS microglia gradually lose their immune functions - not consistent with simple GPNMB-loss model

PMID:38577970

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.